Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 525 matching trials from the live ClinicalTrials.gov search.
Filters: "amyloid" Condition: Alzheimer's Disease Clear all
Recruiting Phase 1Phase 2 Interventional

Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)

NCT06597942
View directory record Official record
Conditions
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease, Moderate Alzheimer&Amp;Amp;#39;s Disease, Alzheimer&Amp;#39;s Disease (AD), Alzheimer&Amp;#39;s Dementia
Interventions
TMS, Transcranial Magnetic Stimulation Sham
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 2, 2026, 2:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

NCT02061878
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
ReXceptor, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 2, 2026, 2:05 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

NCT03821857
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18-F-Flortaucipir
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 2, 2026, 2:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

NCT07651319
View directory record Official record
Conditions
Alzheimer Dementia (AD)
Interventions
IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 2, 2026, 2:05 PM EDT
Recruiting No phase listed Observational

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

NCT06566170
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Usual Care
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 2, 2026, 2:05 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers

NCT05601856
View directory record Official record
Conditions
Alzheimer Disease, Gut Biome
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years to 90 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 2, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Brain Aging in Vietnam War Veterans

NCT01687153
View directory record Official record
Conditions
Traumatic Brain Injury, Post Traumatic Stress Disorder, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 90 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
19
States / cities
Sun City, Arizona • Irvine, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 2, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Sleep Amyloid, Slow WAve Race and Ethnicity Study

NCT03814603
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PET-MR Scan, PiB
Procedure · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 2, 2026, 2:05 PM EDT
Terminated No phase listed Observational

Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial

NCT02781220
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

NCT01855360
View directory record Official record
Conditions
Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis
Interventions
Tauroursodeoxycholic Acid and Doxycycline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 2, 2026, 2:05 PM EDT
Recruiting Phase 2 Interventional

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

NCT06489548
View directory record Official record
Conditions
Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

NCT05291234
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-916, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Tucson, Arizona • Irvine, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting

NCT04309500
View directory record Official record
Conditions
Mild Cognitive Impairment, Healthy Aging
Interventions
Personalized DAT Risk Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

A Phase 3 Study of NE3107 in Probable Alzheimer's Disease

NCT04669028
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 2, 2026, 2:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Plaque and Tangle Imaging in Aging and Dementia

NCT00355498
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Choline Effects - Pre-symptomatic AD

NCT05880849
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Choline
Drug
Lead sponsor
Paul E Schulz
Other
Eligibility
55 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 2, 2026, 2:05 PM EDT
Recruiting No phase listed Observational

F 18 T807 Tau PET Imaging of Alzheimer's Disease

NCT02414347
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

NCT04032626
View directory record Official record
Conditions
Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration, Inflammation, Brain
Interventions
Lenalidomide 10 mg, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Phoenix, Arizona • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

NCT04118764
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Definity, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid
Device · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study

NCT01729598
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

NCT00329082
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2062430, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

NCT01447719
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 2, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

NCT02353598
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Crenezumab dose level 1, Crenezumab dose level 2, Crenezumb dose level 3, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Delray Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 2, 2026, 2:05 PM EDT